These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 17436565

  • 1. DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents.
    Papadopoulou MV, Bloomer WD.
    In Vivo; 2007; 21(2):175-80. PubMed ID: 17436565
    [Abstract] [Full Text] [Related]

  • 2. Mechanisms involved in the potentiation of paclitaxel or 5-fU by the hypoxic cytotoxin NLCQ-1 (NSC 709257) in vitro.
    Papadopoulou MV, Ji X, Bloomer WD.
    Anticancer Res; 2005; 25(3B):2161-70. PubMed ID: 16158959
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro.
    Papadopoulou MV, Ji M, Khan SH, Bloomer WD.
    Oncol Res; 1999; 11(8):345-57. PubMed ID: 10803738
    [Abstract] [Full Text] [Related]

  • 4. Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo.
    Papadopoulou MV, Ji X, Bloomer WD.
    J Exp Ther Oncol; 2006; 5(4):261-72. PubMed ID: 17024967
    [Abstract] [Full Text] [Related]

  • 5. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug.
    Papadopoulou MV, Bloomer WD.
    Clin Cancer Res; 2003 Nov 15; 9(15):5714-20. PubMed ID: 14654556
    [Abstract] [Full Text] [Related]

  • 6. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 2001 Nov 15; 12(8):325-33. PubMed ID: 11589303
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization.
    Taverna P, Hwang HS, Schupp JE, Radivoyevitch T, Session NN, Reddy G, Zarling DA, Kinsella TJ.
    Cancer Res; 2003 Feb 15; 63(4):838-46. PubMed ID: 12591735
    [Abstract] [Full Text] [Related]

  • 8. Recovery from sublethal and potentially lethal damage in an X-ray-sensitive CHO cell.
    Schwartz JL, Giovanazzi S, Weichselbaum RR.
    Radiat Res; 1987 Jul 15; 111(1):58-67. PubMed ID: 3602355
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
    Papadopoulou MV, Ji M, Ji X, Bloomer WD, Hollingshead MG.
    Cancer Chemother Pharmacol; 2002 Dec 15; 50(6):501-8. PubMed ID: 12451478
    [Abstract] [Full Text] [Related]

  • 10. Hypoxia-dependent retinal toxicity of NLCQ-1 (NSC 709257) in BALB/c mice. Comparison with tirapazamine.
    Papadopoulou MV, Ji M, Bloomer WD.
    Basic Clin Pharmacol Toxicol; 2011 Jun 15; 108(6):396-9. PubMed ID: 21205223
    [Abstract] [Full Text] [Related]

  • 11. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
    Papadopoulou MV, Ji M, Bloomer WD.
    Cancer Chemother Pharmacol; 2001 Aug 15; 48(2):160-8. PubMed ID: 11561782
    [Abstract] [Full Text] [Related]

  • 12. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.
    Fracasso PM, Sartorelli AC.
    Cancer Res; 1986 Aug 15; 46(8):3939-44. PubMed ID: 3089583
    [Abstract] [Full Text] [Related]

  • 13. The role of nonhomologous DNA end joining, conservative homologous recombination, and single-strand annealing in the cell cycle-dependent repair of DNA double-strand breaks induced by H(2)O(2) in mammalian cells.
    Frankenberg-Schwager M, Becker M, Garg I, Pralle E, Wolf H, Frankenberg D.
    Radiat Res; 2008 Dec 15; 170(6):784-93. PubMed ID: 19138034
    [Abstract] [Full Text] [Related]

  • 14. Effect of deficiencies in DNA repair on the toxicity of mitomycin C and porfiromycin to CHO cells under aerobic and hypoxic conditions.
    Hughes CS, Irvin CG, Rockwell S.
    Cancer Commun; 1991 Feb 15; 3(2):29-35. PubMed ID: 1899798
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine.
    Papadopoulou MV, Ji M, Ji X, Bloomer WD.
    Cancer Chemother Pharmacol; 2002 Oct 15; 50(4):291-8. PubMed ID: 12357303
    [Abstract] [Full Text] [Related]

  • 16. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): a novel DNA-affinic bioreductive agent as chemosensitizer. I.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 1997 Oct 15; 9(5):249-57. PubMed ID: 9306432
    [Abstract] [Full Text] [Related]

  • 17. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo.
    Papadopoulou MV, Ji M, Bloomer WD.
    Int J Radiat Oncol Biol Phys; 1998 Nov 01; 42(4):775-9. PubMed ID: 9845094
    [Abstract] [Full Text] [Related]

  • 18. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamine.
    Papadopoulou MV, Ji M, Bloomer WD.
    Oncol Res; 2002 Nov 01; 13(1):47-54. PubMed ID: 12201674
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of DNA repair in cells treated with a combination of alkylating agents.
    Frankfurt OS, Seckinger D, Sugarbaker EV.
    Anticancer Res; 1993 Nov 01; 13(4):947-52. PubMed ID: 8352564
    [Abstract] [Full Text] [Related]

  • 20. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin.
    Kovacs MS, Hocking DJ, Evans JW, Siim BG, Wouters BG, Brown JM.
    Br J Cancer; 1999 Jun 01; 80(8):1245-51. PubMed ID: 10376978
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.